CRISPR Therapeutics AG (CRSP) closed the latest trading day at $41.22, indicating a +0.12% change from the previous session's end. This change outpaced the S&P 500's 0.08% gain on the day. On the ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.

The last few weeks of cascading share prices may be troublesome to most investors, but Cathie Wood doesn't mind buying during the deluge. The co-founder, CEO, and investment manager at Ark Invest has ...

The masterclass will serve as a global platform bridging the gap between cutting-edge scientific discoveries and their ...